Treatment outcomes of proton or carbon ion therapy for skull base chordoma: a retrospective study

Masaru Takagi, Yusuke Demizu, Fumiko Nagano, Kazuki Terashima, Osamu Fujii, Dongcun Jin, Masayuki Mima, Yasue Niwa, Kuniaki Katsui, Masaki Suga, Tomohiro Yamashita, Takashi Akagi, Koh ichi Sakata, Nobukazu Fuwa, Tomoaki Okimoto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: The usefulness of particle therapy for skull base chordoma has not been established. The aim of this retrospective study was to analyse the treatment outcomes of proton therapy (PT) and carbon ion therapy (CIT) in patients with skull base chordoma at a single institution. Methods: All patients who underwent PT or CIT with curative intent between 2003 and 2014 at Hyogo Ion Beam Medical Center were included in this study. Twenty-four patients were enrolled. Eleven (46%) received PT and 13 (54%) received CIT. Overall survival (OS), progression-free survival (PFS) and local control (LC) were calculated using the Kaplan-Meier method. Late toxicities were evaluated according to the Common Terminology Criteria for Adverse Events version 4.0. Results: The median follow-up was 71.5 months (range, 14-175 months). The five-year LC, PFS and OS rates were 85, 81, and 86%, respectively. The LC (P = 0.048), PFS (P = 0.028) and OS (P = 0.012) were significantly improved in patients who had undergone surgery before particle therapy. No significant differences were observed in the LC rate and the incidence of grade 2 or higher late toxicities between patients who received PT and CIT. Conclusions: Both PT and CIT appear to be effective and safe treatments and show potential to become the standard treatments for skull base chordoma. To increase the local control, surgery before particle therapy is preferable.

Original languageEnglish
Article number232
JournalRadiation Oncology
Volume13
Issue number1
DOIs
Publication statusPublished - Nov 26 2018

Fingerprint

Heavy Ion Radiotherapy
Proton Therapy
Chordoma
Skull Base
Protons
Retrospective Studies
Disease-Free Survival
Therapeutics
Survival
Terminology
Survival Rate
Ions
Incidence

Keywords

  • Carbon ion therapy
  • Late toxicity
  • Local control
  • Proton therapy
  • Radiotherapy
  • Skull base chordoma
  • Surgery

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Takagi, M., Demizu, Y., Nagano, F., Terashima, K., Fujii, O., Jin, D., ... Okimoto, T. (2018). Treatment outcomes of proton or carbon ion therapy for skull base chordoma: a retrospective study. Radiation Oncology, 13(1), [232]. https://doi.org/10.1186/s13014-018-1173-0

Treatment outcomes of proton or carbon ion therapy for skull base chordoma : a retrospective study. / Takagi, Masaru; Demizu, Yusuke; Nagano, Fumiko; Terashima, Kazuki; Fujii, Osamu; Jin, Dongcun; Mima, Masayuki; Niwa, Yasue; Katsui, Kuniaki; Suga, Masaki; Yamashita, Tomohiro; Akagi, Takashi; Sakata, Koh ichi; Fuwa, Nobukazu; Okimoto, Tomoaki.

In: Radiation Oncology, Vol. 13, No. 1, 232, 26.11.2018.

Research output: Contribution to journalArticle

Takagi, M, Demizu, Y, Nagano, F, Terashima, K, Fujii, O, Jin, D, Mima, M, Niwa, Y, Katsui, K, Suga, M, Yamashita, T, Akagi, T, Sakata, KI, Fuwa, N & Okimoto, T 2018, 'Treatment outcomes of proton or carbon ion therapy for skull base chordoma: a retrospective study', Radiation Oncology, vol. 13, no. 1, 232. https://doi.org/10.1186/s13014-018-1173-0
Takagi, Masaru ; Demizu, Yusuke ; Nagano, Fumiko ; Terashima, Kazuki ; Fujii, Osamu ; Jin, Dongcun ; Mima, Masayuki ; Niwa, Yasue ; Katsui, Kuniaki ; Suga, Masaki ; Yamashita, Tomohiro ; Akagi, Takashi ; Sakata, Koh ichi ; Fuwa, Nobukazu ; Okimoto, Tomoaki. / Treatment outcomes of proton or carbon ion therapy for skull base chordoma : a retrospective study. In: Radiation Oncology. 2018 ; Vol. 13, No. 1.
@article{287480b8ac5c4aa4bd818fb9149d44ff,
title = "Treatment outcomes of proton or carbon ion therapy for skull base chordoma: a retrospective study",
abstract = "Background: The usefulness of particle therapy for skull base chordoma has not been established. The aim of this retrospective study was to analyse the treatment outcomes of proton therapy (PT) and carbon ion therapy (CIT) in patients with skull base chordoma at a single institution. Methods: All patients who underwent PT or CIT with curative intent between 2003 and 2014 at Hyogo Ion Beam Medical Center were included in this study. Twenty-four patients were enrolled. Eleven (46{\%}) received PT and 13 (54{\%}) received CIT. Overall survival (OS), progression-free survival (PFS) and local control (LC) were calculated using the Kaplan-Meier method. Late toxicities were evaluated according to the Common Terminology Criteria for Adverse Events version 4.0. Results: The median follow-up was 71.5 months (range, 14-175 months). The five-year LC, PFS and OS rates were 85, 81, and 86{\%}, respectively. The LC (P = 0.048), PFS (P = 0.028) and OS (P = 0.012) were significantly improved in patients who had undergone surgery before particle therapy. No significant differences were observed in the LC rate and the incidence of grade 2 or higher late toxicities between patients who received PT and CIT. Conclusions: Both PT and CIT appear to be effective and safe treatments and show potential to become the standard treatments for skull base chordoma. To increase the local control, surgery before particle therapy is preferable.",
keywords = "Carbon ion therapy, Late toxicity, Local control, Proton therapy, Radiotherapy, Skull base chordoma, Surgery",
author = "Masaru Takagi and Yusuke Demizu and Fumiko Nagano and Kazuki Terashima and Osamu Fujii and Dongcun Jin and Masayuki Mima and Yasue Niwa and Kuniaki Katsui and Masaki Suga and Tomohiro Yamashita and Takashi Akagi and Sakata, {Koh ichi} and Nobukazu Fuwa and Tomoaki Okimoto",
year = "2018",
month = "11",
day = "26",
doi = "10.1186/s13014-018-1173-0",
language = "English",
volume = "13",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Treatment outcomes of proton or carbon ion therapy for skull base chordoma

T2 - a retrospective study

AU - Takagi, Masaru

AU - Demizu, Yusuke

AU - Nagano, Fumiko

AU - Terashima, Kazuki

AU - Fujii, Osamu

AU - Jin, Dongcun

AU - Mima, Masayuki

AU - Niwa, Yasue

AU - Katsui, Kuniaki

AU - Suga, Masaki

AU - Yamashita, Tomohiro

AU - Akagi, Takashi

AU - Sakata, Koh ichi

AU - Fuwa, Nobukazu

AU - Okimoto, Tomoaki

PY - 2018/11/26

Y1 - 2018/11/26

N2 - Background: The usefulness of particle therapy for skull base chordoma has not been established. The aim of this retrospective study was to analyse the treatment outcomes of proton therapy (PT) and carbon ion therapy (CIT) in patients with skull base chordoma at a single institution. Methods: All patients who underwent PT or CIT with curative intent between 2003 and 2014 at Hyogo Ion Beam Medical Center were included in this study. Twenty-four patients were enrolled. Eleven (46%) received PT and 13 (54%) received CIT. Overall survival (OS), progression-free survival (PFS) and local control (LC) were calculated using the Kaplan-Meier method. Late toxicities were evaluated according to the Common Terminology Criteria for Adverse Events version 4.0. Results: The median follow-up was 71.5 months (range, 14-175 months). The five-year LC, PFS and OS rates were 85, 81, and 86%, respectively. The LC (P = 0.048), PFS (P = 0.028) and OS (P = 0.012) were significantly improved in patients who had undergone surgery before particle therapy. No significant differences were observed in the LC rate and the incidence of grade 2 or higher late toxicities between patients who received PT and CIT. Conclusions: Both PT and CIT appear to be effective and safe treatments and show potential to become the standard treatments for skull base chordoma. To increase the local control, surgery before particle therapy is preferable.

AB - Background: The usefulness of particle therapy for skull base chordoma has not been established. The aim of this retrospective study was to analyse the treatment outcomes of proton therapy (PT) and carbon ion therapy (CIT) in patients with skull base chordoma at a single institution. Methods: All patients who underwent PT or CIT with curative intent between 2003 and 2014 at Hyogo Ion Beam Medical Center were included in this study. Twenty-four patients were enrolled. Eleven (46%) received PT and 13 (54%) received CIT. Overall survival (OS), progression-free survival (PFS) and local control (LC) were calculated using the Kaplan-Meier method. Late toxicities were evaluated according to the Common Terminology Criteria for Adverse Events version 4.0. Results: The median follow-up was 71.5 months (range, 14-175 months). The five-year LC, PFS and OS rates were 85, 81, and 86%, respectively. The LC (P = 0.048), PFS (P = 0.028) and OS (P = 0.012) were significantly improved in patients who had undergone surgery before particle therapy. No significant differences were observed in the LC rate and the incidence of grade 2 or higher late toxicities between patients who received PT and CIT. Conclusions: Both PT and CIT appear to be effective and safe treatments and show potential to become the standard treatments for skull base chordoma. To increase the local control, surgery before particle therapy is preferable.

KW - Carbon ion therapy

KW - Late toxicity

KW - Local control

KW - Proton therapy

KW - Radiotherapy

KW - Skull base chordoma

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=85057187809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057187809&partnerID=8YFLogxK

U2 - 10.1186/s13014-018-1173-0

DO - 10.1186/s13014-018-1173-0

M3 - Article

C2 - 30477528

AN - SCOPUS:85057187809

VL - 13

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 232

ER -